Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

This week, CancerNetwork® spoke with Judd W. Moul, MD, editorial board member for the journal ONCOLOGY® and James H. Semans, MD, Distinguished Professor of Urologic Surgery at Duke University School of Medicine, leads a discussion with medical student Kostantinos E. Morris, from Duke University School of Medicine, on research recently published in the journal ONCOLOGY®titled, ‘Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.’

The manuscript was based on the case of a patient who presented to their clinic with elevated prostate-specific antigen (PSA) levels and multiple imaging tests that appeared to indicate an absence of malignancy. Their discussion includes why they continued to investigate the cause of the elevated PSA levels, how they overcame the patient’s hesitation for more testing, and the ultimate outcome of the case.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
Related Content